Your browser doesn't support javascript.
loading
A Randomized Controlled Trial to Prevent Depression and Ameliorate Insulin Resistance in Adolescent Girls at Risk for Type 2 Diabetes.
Shomaker, Lauren B; Kelly, Nichole R; Pickworth, Courtney K; Cassidy, Omni L; Radin, Rachel M; Shank, Lisa M; Vannucci, Anna; Thompson, Katherine A; Armaiz-Flores, Sara A; Brady, Sheila M; Demidowich, Andrew P; Galescu, Ovidiu A; Courville, Amber B; Olsen, Cara; Chen, Kong Y; Stice, Eric; Tanofsky-Kraff, Marian; Yanovski, Jack A.
Afiliação
  • Shomaker LB; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA. lauren.shomaker@colostat
  • Kelly NR; Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda, MD, 20814-4712, USA. lauren.shomaker@colostate.edu.
  • Pickworth CK; Department of Human Development and Family Studies and Colorado School of Public Health, Colorado State University, 303A Behavioral Sciences Building, 410 Pitkin Street, Campus Delivery 1570, Fort Collins, CO, 80523-1570, USA. lauren.shomaker@colostate.edu.
  • Cassidy OL; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Radin RM; Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda, MD, 20814-4712, USA.
  • Shank LM; Department of Human Development and Family Studies and Colorado School of Public Health, Colorado State University, 303A Behavioral Sciences Building, 410 Pitkin Street, Campus Delivery 1570, Fort Collins, CO, 80523-1570, USA.
  • Vannucci A; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Thompson KA; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Armaiz-Flores SA; Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda, MD, 20814-4712, USA.
  • Brady SM; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Demidowich AP; Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda, MD, 20814-4712, USA.
  • Galescu OA; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Courville AB; Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda, MD, 20814-4712, USA.
  • Olsen C; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Chen KY; Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences (USUHS), 4301 Jones Bridge Road, Bethesda, MD, 20814-4712, USA.
  • Stice E; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Tanofsky-Kraff M; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
  • Yanovski JA; Section on Growth and Obesity, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Hatfield Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC 1103, Bethesda, MD, 20892-1103, USA.
Ann Behav Med ; 50(5): 762-774, 2016 10.
Article em En | MEDLINE | ID: mdl-27333897
BACKGROUND: Prospective data suggest depressive symptoms worsen insulin resistance and accelerate type 2 diabetes (T2D) onset. PURPOSE: We sought to determine whether reducing depressive symptoms in overweight/obese adolescents at risk for T2D would increase insulin sensitivity and mitigate T2D risk. METHOD: We conducted a parallel-group, randomized controlled trial comparing a 6-week cognitive-behavioral (CB) depression prevention group with a 6-week health education (HE) control group in 119 overweight/obese adolescent girls with mild-to-moderate depressive symptoms (Center for Epidemiological Studies-Depression Scale [CES-D] ≥16) and T2D family history. Primary outcomes were baseline to post-intervention changes in CES-D and whole body insulin sensitivity index (WBISI), derived from 2-h oral glucose tolerance tests. Outcome changes were compared between groups using ANCOVA, adjusting for respective baseline outcome, puberty, race, facilitator, T2D family history degree, baseline age, adiposity, and adiposity change. Multiple imputation was used for missing data. RESULTS: Depressive symptoms decreased (p < 0.001) in CB and HE from baseline to posttreatment, but did not differ between groups (ΔCESD = -12 vs. -11, 95 % CI difference = -4 to +1, p = 0.31). Insulin sensitivity was stable (p > 0.29) in CB and HE (ΔWBISI = 0.1 vs. 0.2, 95 % CI difference = -0.6 to +0.4, p = 0.63). Among all participants, reductions in depressive symptoms were associated with improvements in insulin sensitivity (p = 0.02). CONCLUSIONS: Girls at risk for T2D displayed reduced depressive symptoms following 6 weeks of CB or HE. Decreases in depressive symptoms related to improvements in insulin sensitivity. Longer-term follow-up is needed to determine whether either program causes sustained decreases in depressive symptoms and improvements in insulin sensitivity. TRIAL REGISTRATION NUMBER: The trial was registered with clinicaltrials.gov (NCT01425905).
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Terapia Cognitivo-Comportamental / Depressão / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Terapia Cognitivo-Comportamental / Depressão / Diabetes Mellitus Tipo 2 Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adolescent / Child / Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article